Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant solid tumor
• * Advanced or unresectable disease
• No standard therapeutic option available
• Evaluable disease (according to RECIST criteria) that has not been previously irradiated
• * Prior radiotherapy to the marker lesion(s) allowed provided there is evidence of progression since radiotherapy
• Brain metastases allowed provided the following criteria are met:
• * CNS-directed treatment was given and was completed \> 3 months ago
• * CNS disease has been clinically and radiographically stable for ≥ 8 weeks
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/µL
• Platelet count ≥ 100,000/µL
• Creatinine clearance ≥ 60 mL/min
• Total bilirubin ≤ 1.2 mg/dL
• Transaminases ≤ 5 times upper limit of normal (ULN)
• Magnesium ≥ lower limit of normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 24 weeks (females) or for 4 weeks (males) after completion of study therapy
• Willing to avoid pregnancy for 3 months after completion of study therapy
• No neuropathy ≥ grade 2
• No concurrent life-threatening acute medical illness
• No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
• No active bleeding diathesis
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 3 weeks since prior major surgery, radiotherapy (including radiotherapy involving the abdomen or spine), chemotherapy, or other systemic anticancer therapy and recovered
• At least 4 weeks since prior investigational drugs
• No concurrent CYP3A4 inducers or inhibitors that cannot be substituted by a different agent
• No concurrent oral anti-vitamin K medication (except for low-dose warfarin)
• No concurrent colony stimulating factors during the first course of treatment